Moors & Cabot
CRL icon

Moors & Cabot’s Charles River Laboratories CRL Stock Holding History

Moors & Cabot’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$502K Sell
1,701
-30
-2% -$7.91K 0.02% 569
2026
Q2 		$393K Buy
1,731
+34
+2% +$6.06K 0.02% 645
2026
Q1 		$293K Buy
1,697
+12
+0.7% +$2.22K 0.01% 711
2025
Q4 		$336K Hold
1,685
– – 0.01% 648
2025
Q3 		$264K Hold
1,685
– – 0.01% 724
2025
Q2 		$256K Sell
1,685
-126
-7% -$16.8K 0.01% 711
2025
Q1 		$273K Sell
1,811
-3
-0.2% -$503 0.01% 672
2024
Q4 		$335K Buy
1,814
+9
+0.5% +$1.73K 0.02% 636
2024
Q3 		$356K Sell
1,805
-190
-10% -$39.5K 0.02% 608
2024
Q2 		$412K Buy
1,995
+18
+0.9% +$4.08K 0.02% 534
2024
Q1 		$536K Sell
1,977
-299
-13% -$71.4K 0.03% 473
2023
Q4 		$538K Sell
2,276
-5
-0.2% -$983 0.03% 443
2023
Q3 		$447K Sell
2,281
-74
-3% -$15.2K 0.03% 469
2023
Q2 		$495K Buy
2,355
+108
+5% +$21.5K 0.03% 448
2023
Q1 		$453K Buy
2,247
+18
+0.8% +$4.08K 0.03% 463
2022
Q4 		$486K Buy
2,229
+90
+4% +$19.7K 0.03% 432
2022
Q3 		$421K Buy
2,139
+151
+8% +$32.6K 0.03% 452
2022
Q2 		$425K Buy
1,988
+100
+5% +$24.4K 0.03% 458
2022
Q1 		$536K Sell
1,888
-10
-0.5% -$3.08K 0.03% 448
2021
Q4 		$715K Buy
1,898
+100
+6% +$38.9K 0.04% 369
2021
Q3 		$743K Buy
+1,798
New +$747K 0.05% 344

Other funds holding CRL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $64.1B AUM 28.9% 1-Year Est. Return
Cooke & Bieler
Cooke & Bieler Philadelphia, Pennsylvania $6.36B AUM 0.55% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $179B AUM 29.92% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $313B AUM 26.62% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Van Berkom & Associates
Van Berkom & Associates Montreal, Quebec, Canada $2.81B AUM 6.02% 1-Year Est. Return
Boston Trust Walden
Boston Trust Walden Boston, Massachusetts $12.4B AUM 21.62% 1-Year Est. Return

Moors & Cabot's CRL Position: Q3 2026 in Review

Moors & Cabot reduced its Charles River Laboratories (CRL) stake by 1.7% in Q3 2026, selling an estimated $7.91K and leaving 1,701 shares worth $502K. The position accounts for 0.02% of the portfolio, ranked #569.

Moors & Cabot first reported a position in CRL in Q3 2021 and has held it in 21 quarters since. The position peaked at $743K in Q3 2021. 332 funds tracked by Wall St. Rank hold CRL as of Q3 2026.

  • Moors & Cabot held 1,701 shares of Charles River Laboratories worth $502K as of Q3 2026.
  • Moors & Cabot sold 30 Charles River Laboratories shares in Q3 2026, an estimated $7.91K.
  • Charles River Laboratories made up 0.02% of Moors & Cabot's portfolio in Q3 2026, its #569 holding.
  • Moors & Cabot first reported a position in Charles River Laboratories in Q3 2021 and has held it in 21 quarters since.
  • Moors & Cabot's Charles River Laboratories position peaked at $743K in Q3 2021.
  • 332 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2026.

Based on Moors & Cabot's 13F filing for Q3 2026, filed 6 Nov 2026.